Research programme: secondary hyperparathyroidism therapies - OPKO HealthAlternative Names: CTA 091
Latest Information Update: 24 Apr 2014
At a glance
- Originator OPKO Health
- Class Vitamin D analogues
- Mechanism of Action CYP24 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Secondary hyperparathyroidism
Most Recent Events
- 24 Apr 2014 Preclinical trials in Secondary hyperparathyroidism in USA (unspecified route)